A Multiple Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Multiple Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2018
At a glance
- Drugs NN 9277 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 25 Oct 2018 Status changed from active, no longer recruiting to recruiting.
- 01 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 07 Nov 2017 Planned End Date changed from 18 Dec 2018 to 23 Dec 2018.